What injection duration actually means in practice

Duration ranges from a few days to potentially two years or more — but that single figure tells a patient very little without knowing what job the injection is meant to do.

The four main categories used in knee osteoarthritis — corticosteroids, hyaluronic acid (HA), platelet-rich plasma (PRP), and polyacrylamide hydrogel — are not interchangeable. Some are designed for short-term symptom relief during an acute flare; others aim at longer functional benefit or structural support. The distinction is not semantic: these injections are doing different jobs, and choosing between them depends as much on the stage of a patient's OA and their treatment goals as on how many months of relief a label promises.

Disease severity is one of the strongest modifiers of outcome. Patients with end-stage OA consistently respond less well to injections across all types, and excluding them from trials significantly improves the apparent benefit seen in published data — meaning real-world durability is often lower than headline figures suggest.

A further caveat applies across the board: the placebo response in knee OA injection trials is substantial and well-documented. Duration estimates drawn from uncontrolled or non-placebo-controlled studies are likely to overstate real-world effect, and patients should factor this in when comparing claims.

Finally, no head-to-head randomised controlled trial has directly compared all four injection types in the same population. Any ranking of their relative durability is evidence-informed, not evidence-definitive.

Corticosteroid injections and their short window of relief

For most patients, a corticosteroid injection offers a window of relief measured in weeks — not months. The exact length depends on the formulation chosen.

Soluble, short-acting preparations work quickly, sometimes easing pain within hours of the injection. That speed comes at a cost: the effect typically lasts around one week before it fades. Less soluble depot formulations — triamcinolone is the most widely used — take roughly a week to reach full effect but can ease symptoms for two months or longer in many patients. No single formulation has been shown to be clearly superior to the others overall.

What all corticosteroids share is a ceiling on what they can achieve. They reduce local inflammation and dampen pain signals, but they do not slow or reverse the underlying joint degeneration. The relief is real and can be clinically valuable — but it is borrowed time, not treatment progress.

Repeated high-frequency injections carry a documented concern about cartilage safety over time. This is not a reason to avoid a single injection when one is warranted, but it is why clinicians tend to limit how often they are given and avoid treating them as a repeating cycle.

The appropriate role is narrower and more specific: managing an acute flare, allowing a patient to engage with physiotherapy, or bridging to a more durable treatment. Used in that context, the short duration is a feature of the design rather than a shortcoming.

Hyaluronic acid and the six-month benchmark

Six months is the figure most commonly cited for hyaluronic acid (HA) injections, and for appropriate candidates it remains a reasonable benchmark — though the evidence behind it is more contested than a single number implies.

The first complication is the single-versus-multiple injection debate. Protocols range from a single injection to a course of up to five, administered a week apart. A systematic review of 11 head-to-head trials found no consistent difference in patient-reported outcomes between single and multi-injection regimens. Yet a separate network meta-analysis (Bannuru et al., Annals of Internal Medicine, 2015) found that 2–4 injection courses and regimens of five or more outperformed saline, while single-injection protocols did not show this advantage. The two bodies of evidence have not been reconciled, and clinicians draw different conclusions from them. Patients should be aware that neither camp has definitively won the argument.

Single-injection products — particularly high-molecular-weight or reticulated formulations — are attracting growing clinical interest precisely because they reduce the number of procedural visits. Whether this comes at the cost of durability compared with multi-injection courses is not yet settled.

The second complication concerns who was in the trials. Studies that exclude patients with end-stage OA consistently show stronger apparent treatment effects. For patients whose disease is already advanced, the real-world benefit of HA may be considerably more modest than headline six-month figures suggest.

Unlike polyacrylamide hydrogel, HA is absorbed by the body over time and does not integrate structurally into synovial tissue. When benefit attenuates — as it eventually will — a repeat injection cycle is typically the next step rather than a permanent solution.

PRP injections and sustained benefit up to two years

Among the biologic injectables supported by randomised trial data, PRP offers the longest documented window of meaningful relief — consistent benefit at 12 months, with some patients reporting improvement beyond 24 months before a gradual attenuation of effect. Re-injection should be anticipated rather than treated as a treatment failure.

Protocol and patient selection shape that window considerably. Three-injection courses have shown better synovial inflammation reduction and more durable results than a single injection in preclinical data, and leukocyte-poor formulations are generally preferred in clinical practice — leukocyte-rich preparations tend to produce more post-injection pain and swelling in the short term. These are current clinical preferences rather than fixed rules, and practice varies.

Younger patients with moderate OA respond best. End-stage disease is associated with a weaker, shorter-lasting response — a pattern consistent with what has been observed across other injection types, and a reminder that disease severity remains one of the strongest predictors of outcome.

The guideline picture is genuinely unsettled. AAOS and ACR have withheld a recommendation for PRP in knee OA, citing heterogeneity in the evidence — different PRP preparations, different patient groups, and different outcome measures across trials make direct comparison difficult. OARSI, by contrast, does support its use. This disagreement reflects the study landscape rather than a verdict on PRP's effectiveness, and the evidence base is growing rapidly.

What robust evidence has not yet defined is the optimal re-injection interval. Clinical practice varies, and patients should expect that guidance on timing will continue to evolve as longer-term data accumulate.

Polyacrylamide hydrogel as the longest-lasting single injection

Polyacrylamide hydrogel — marketed as Arthrosamid® — occupies a distinct category from everything covered so far. Rather than supplementing joint fluid, it works by a different mechanism entirely: once injected, it integrates into the synovial lining of the joint as a semi-permanent cushioning scaffold. Because it is not absorbed over time, the durability argument rests on biology rather than on a claim that any effect has simply been stretched out.

The available clinical evidence is encouraging, though still limited in scope. A 24-month patient-reported outcomes cohort study — 269 patients across 314 knees — found sustained benefit at follow-up, and a 12-month open-label study (Bliddal et al., Journal of Orthopaedic Surgery and Research, 2024) confirmed both effectiveness and safety over that period. On current published data, this represents the longest documented benefit window attributable to a single injection of any type.

The practical appeal is straightforward: one injection, with no built-in re-injection schedule. For patients weighing up procedural burden alongside duration, that distinction matters.

The limitations, however, deserve equal prominence. These studies are observational and open-label — the randomised controlled trial data that underpin confidence in HA and PRP at scale are not yet available for polyacrylamide hydrogel. Safety data beyond 24 months remain limited, and which patients are most likely to respond well has not been systematically established.

The honest position is that this is a mechanistically novel option with the longest single-injection evidence window currently published, supported by a promising but still-maturing evidence base.

What affects how long any injection works for you

Two patients receiving the same injection in the same clinic can come away with very different durations of benefit — and the product itself is rarely the only explanation.

Disease severity is the most consistent predictor across all four injection types. End-stage OA responds poorly regardless of what is injected; the evidence for HA, PRP, and polyacrylamide hydrogel all point in the same direction on this point. Earlier-stage disease, treated at the right moment, offers the best chance of a sustained response.

Age, body weight, and activity level each contribute. Higher joint load — from body weight or occupational demands — shortens the interval before symptoms return. Younger patients with moderate cartilage loss tend to fare better, particularly with PRP.

Protocol and formulation matter independently of product category. Whether someone receives one injection or three, and which specific preparation is used, shifts the outcome meaningfully — a reminder that comparing products without comparing protocols can be misleading.

Interpreting anecdotal accounts and single-arm studies also requires caution: the placebo response in injection research is large enough to inflate apparent benefit considerably, making population-level averages unreliable guides to individual prediction.

What remains unresolved — across all injection types — is when re-injection is optimally timed. Current practice is guided by clinical judgement rather than robust trial data. Which injection type, which protocol, and which timing interval suits a specific patient's disease stage and circumstances is a question best worked through in a specialist assessment rather than answered by population averages alone.

1. [1] Osteoarthritis — Wikipedia. https://en.wikipedia.org/?curid=504841 https://en.wikipedia.org/?curid=504841
2. [2] Joint injection — Wikipedia. https://en.wikipedia.org/?curid=1425459 https://en.wikipedia.org/?curid=1425459